Carnitine Metabolite as a Potential Circulating Biomarker for Sarcopenia in Men.

Je Hyun Seo, Jung-Min Koh, Han Jin Cho, Hanjun Kim, Young-Sun Lee, Su Jung Kim, Pil Whan Yoon, Won Kim, Sung Jin Bae, Hong-Kyu Kim, Hyun Ju Yoo, Seung Hun Lee

Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Korea. · pubmed

Paper

Abstract

Sarcopenia, a multifactorial disorder involving metabolic disturbance, suggests potential for metabolite biomarkers. Carnitine (CN), essential for skeletal muscle energy metabolism, may be a candidate biomarker. We investigated whether CN metabolites are biomarkers for sarcopenia.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the potential of carnitine metabolites as biomarkers for sarcopenia, which is an age-related condition affecting muscle mass and function. While it touches on a significant aspect of aging, the focus on biomarkers suggests a more symptomatic approach rather than addressing the root causes of aging itself. The findings may contribute to the understanding of sarcopenia but do not present a major breakthrough or transformative implications for longevity research.

Author of this paper? Send a correction.